Menu
Home
Log in / Register
 
Home arrow Health arrow Cognitive impairment and dementia in Parkinson disease
Source

References

  • 1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689-707.
  • 2. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92.
  • 3. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
  • 4. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated caregiver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42.
  • 5. Bronnick K, Aarsland D, Larsen JP. Neuropsychiatric disturbances in Parkinson’s disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand 2005; 112: 201-7.
  • 6. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67: 492-6.
  • 7. Leroi I, Pantula H, McDonald K, et al. Neuropsychiatric symptoms in Parkinson’s disease with mild cognitive impairment and dementia. Parkinson’s Dis 2012; art ID 308097. doi: 10.1155/2012/308097
  • 8. Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson’s disease with dementia and Alzheimer’s disease. Int J Geriatr Psychiatry 2001; 16: 184-91.
  • 9. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001; 13: 42-9.
  • 10. Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry 2001;
  • 16: 528-36.
  • 11. Galvin JE, Pollack J, Morris J. Clinical phenotype of Parkinson disease dementia. Neurology 2006; 67: 1605-11.
  • 12. Lieberman A. Are dementia and depression in Parkinson’s disease related? Neurol Sci 2006; 248: 138-42.
  • 13. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in longstanding Parkinson’s disease. J Neural Transm 2000; 107: 59-71.
  • 14. Emre M. What causes mental dysfunction in Parkinson’s disease? Mov Disord 2003; 18(Suppl. 6): S63-S71.
  • 15. Hoehn MH, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-42.
  • 16. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson’s disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34: 465-70.
  • 17. Richard IH, Justus AW, Kurlan R. Relationship between mood and motor fluctuations in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001; 13: 35-41.
  • 18. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002; 59: 408-13.
  • 19. Racette BA, Hartlein JM, Hershey T, et al. Clinical features and comorbidity of mood fluctuations in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2002; 14: 438-42.
  • 20. Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol 2010; 257: 1073-82.
  • 21. Hirono N, Mori E, Tanimukai S, et al. Distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci 1999; 11: 498-503.
  • 22. Benoit M, Robert P, Staccini P, et al. One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer’s disease. The REAL.FR Study. J Nutr Health Aging 2005; 9: 134-9.
  • 23. Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992; 4: 134-9.
  • 24. Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73: 636-42.
  • 25. Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson’s disease. Mov Disord 2007; 22: 778-84.
  • 26. Sockeel P, Dujardin K, Devos D, et al. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77: 579-84.
  • 27. Dujardin K, Sockeel P, Delliaux M, et al. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 2009; 24: 2391-7.
  • 28. Santangelo G, Trojano L, Vitale C, et al. A neuropsychological longitudinal study in Parkinson’s patients with and without hallucinations. Mov Disord 2007; 22: 2418-25.
  • 29. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 1993; 43: 2227-9.
  • 30. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al., for the Trapecio Group Study. Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov Disord 2008;
  • 23: 1889-96.
  • 31. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-45.
  • 32. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2001; 70: 734-8.
  • 33. Mosimann UP, Rowan EN, Partington C, et al. Characteristics of visual hallucinations in Parkinson’s disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry 2006; 14: 153-60.
  • 34. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64: 533-5.
  • 35. Fenelon G, Thobois S, Bonnet AM, et al. Tactile hallucinations in Parkinson’s disease. J Neurol 2002; 249: 1699-703.
  • 36. Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson’s disease. Parkinsonism Relat Disord 2004; 10: 253-4.
  • 37. Goetz CG, Wuu J, Curgian L, et al. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson’s disease patients. Mov Disord 2006; 21: 267-70.
  • 38. Arnulf I, Bonnet A-M, Damier P, et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology 2000; 55: 281-8.
  • 39. Pappert E, Goetz C, Niederman F. Hallucinations, sleep fragmentation and altered dream phenomena in Parkinson’s disease. Mov Disord 1999; 14: 117-21.
  • 40. Smith MC, Ellgring H, Oertel WH. Sleep disturbances in Parkinson’s disease patients and spouses. J Am Geriatr Soc 1997; 45: 194-9.
  • 41. Stacy M. Sleep disorders in Parkinson’s disease. Drugs Aging 2002; 19: 733-9.
  • 42. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov Disord 1999; 14: 922-7.
  • 43. Friedman J, Friedman H. Fatigue in Parkinson’s disease. Neurology 1993; 43: 2016-18.
  • 44. Hitten JJ, van Hoogland G, van der Velde EA, et al. Diurnal effects of motor activity and fatigue in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1993; 56: 874-7.
  • 45. Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes in Parkinson’s disease. Mov Disord 2000; 15: 212-15.
  • 46. Postuma R, Bertrand J, Montplaisir J, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson’s disease: a prospective study. Mov Disord 2012; 27: 720-6.
  • 47. Compta Y, Santamaria J, Ratti L, et al. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson’s disease dementia. Brain 2009; 132: 3308-17.
  • 48. Johns M. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540-5.
  • 49. Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectrums 2006; 11: 1-7.
  • 50. Phuong L, Garg S, Duda JE, et al. Involuntary emotional disorder in Parkinson’s disease. Parkinsonism Relat Disord 2009; 15: 511-15.
  • 51. Galpern W, Stacy M. Management of impulse control disorders in Parkinson’s disease. Curr Opin Neurol 2007; 9: 189-97.
  • 52. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007; 64: 1089-96.
  • 53. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969-73.
  • 54. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathological gambling and medication association in Parkinson disease. Neurology 2006; 66: 1750-2.
  • 55. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006; 67: 1254-7.
  • 56. Voon V, Kubu C, Krack P, et al. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21(Suppl. 14): S305-S326.
  • 57. Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease. Mov Disord 2003; 18: 1332-7.
  • 58. Smeding HM, Speelman JD, Koning-Haanstra M, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006; 66: 1830-6.
  • 59. Houeto JL, Mesnage V, Mallet L, et al. Behavioral disorders, Parkinson’s disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701-7.
  • 60. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson’s disease: a consecutive series of 24 patients. Neurology 2002; 59: 1427-9.
  • 61. Witt K, Granert O, Daniels C, et al. Relation of lead traj ectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson’s disease: results from a randomized trial. Brain 2013; 136: 2109-19.
  • 62. Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviors. Brain 2012; 135: 1463-77.
  • 63. Hughes TA, Ross HF, Mindham RH, et al. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 2004; 110: 118-23.
  • 64. Starkstein SE, Bolduc PL, Mayberg HS, et al. Cognitive impairments and depression in Parkinson’s disease: a follow up study. J Neurol Neurosurg Psychiatry 1990; 53: 597-602.
  • 65. Starkstein SE, Mayberg HS, Leiguarda R, et al. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992; 55: 377-82.
  • 66. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61: 1906-11.
  • 67. Ramirez-Ruiz B, Junque C, Marti M, et al. Cognitive changes in Parkinson’s disease patients with visual hallucinations. Dement Geriatr Cogn Disord 2007; 23: 281-8.
  • 68. Aarsland D, Larsen JP, Karlsen K, et al. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866-74.
  • 69. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63: 293-300.
  • 70. Salter B, Andersen KE, Weiner WJ. Psychosis in Parkinson’s disease: case studies. Neurol Clin 2006; 24: 363-9.
  • 71. Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938-42.
  • 72. Goetz CG, Tanner CM, Stebbins GT, et al. Risk factors for progression in Parkinson’s disease. Neurology 1988; 38: 1841-4.
  • 73. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson’s disease: a community- based, prospective study. Neurology 2001; 56: 730-6.
  • 74. Graham J, Grunewald R, Sager H. Hallucinosis in idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 63: 434-40.
  • 75. Aarsland D, Larsen JP, Cummings JL, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56: 595-601.
  • 76. Weintraub D, Moberg PJ, Duda JE, et al. Effect of psychiatric and other non-motor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc 2004; 52: 784-8.
  • 77. Biglan KM, Holloway RG J, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69: 187-95.
  • 78. Biggins C, Boyd J, Harrop F, et al. A controlled, longitudinal study of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992; 55: 566-71.
  • 79. Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 2006; 21: 1123-30.
  • 80. Wint DP, Okun MS, Fernandez HH. Psychosis in Parkinson’s disease. J Geriatr Psychiatry Neurol 2004; 17: 127-36.
  • 81. Weintraub D, Morales KH, Duda JE, et al. Frequency and correlates of co-morbid psychosis and depression in Parkinson’s disease. Parkinsonism Relat Disord 2006; 12: 427-31.
  • 82. Wolters ECh. Intrinsic and extrinsic psychosis in Parkinson’s disease. J Neurol 2001; 248(Suppl. 3): 22-7.
  • 83. Henderson MJ, Mellers JDC. Psychosis in Parkinson’s disease: ‘between a rock and a hard place’. Int Rev Psychiatry 2000; 12: 319-34.
  • 84. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53: 1265-8.
  • 85. Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm 2004; 111: 1447-53.
  • 86. Onofrj M, Thomas A, Bonanni L. New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins. Expert Rev Neurotherapeutics 2007; 7: 1731-50.
  • 87. Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov Disord 2005; 20: 1439-48.
  • 88. Phillips B. Movement disorders: a sleep specialist’s perspective. Neurology 2004; 62(Suppl. 2): S9-S16.
  • 89. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34: 710-14.
  • 90. Chaudhuri A, Behan PO. Fatigue and basal ganglia. J Neurol Sci 2000; 179: 34-42.
  • 91. Karlsen K, Larsen JP, Tandberg E, et al. Fatigue in patients with Parkinson’s disease. Mov Disord 1999; 14: 237-41.
  • 92. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003; 65: 193-207.
  • 93. Mentis MJ, McIntosh AR, Perrine K, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. Am J Psychiatry 2002; 159: 746-54.
  • 94. Mayberg HS, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 1990; 28: 57-64.
  • 95. Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect 1993; 91: 75-109.
  • 96. Berg D, Supprian T, Hofmann E, et al. Depression in Parkinson’s disease: brainstem midline alteration on transcranial sonography and magnetic imaging. J Neurol 1999; 246: 1186-93.
  • 97. Murai T, Muller U, Werheid K, et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001; 13: 222-8.
  • 98. Duffy JD. The neural substrates of motivation. Psychiatr Ann 1997; 27: 39-43.
  • 99. Isella V, Melzi P, Grimaldi M, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov Disord 2002; 17: 366-71.
  • 100. Robert G, Le Jeune F, Lozachmeur C, et al. Apathy in patients with Parkinson disease without dementia or depression: a PET study. Neurology 2012; 79: 1155-60.
  • 101. Wolters ECh. Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology 1999; 52(Suppl. 3): S10-S13.
  • 102. Cheng A, Ferrier I, Morris C, et al. Cortical serotonin S-2 receptor-binding in Lewy body dementia, Alzheimer’s and Parkinson’s diseases. J Neurol Sci 1991; 106: 50-5.
  • 103. Perry E, Marshall E, Kerwin J. Evidence of monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990; 55: 1454-6.
  • 104. Birkmayer W, Danielczyk W, Neumayer E, et al. Nucleus ruber and L-dopa psychosis: biochemical and post-mortem findings. J Neural Transm 1974; 35: 93-116.
  • 105. Jellinger K. The pedunculopontine nucleus in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51: 540-3.
  • 106. Eisensehr I, Linke R, Noachtar S, et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behavior disorder. comparison with Parkinson’s disease and controls. Brain 2000; 123: 1155-60.
  • 107. Green RL. Regulation of affect. Semin Clin Neuropsychiatry 1998; 3: 195-200.
  • 108. Gallagher DA, Goetz CG, Stebbins G, et al. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson’s disease. Mov Disord 2012; 27: 79-83.
  • 109. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and climimetric testing results. Mov Disord 2008; 23: 2129-70.
  • 110. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233-9.
  • 111. Weintraub D, Moberg PJ, Duda JE, et al. Recognition and treatment of depression in Parkinson’s disease. J Geriatr Psychiatry Neurol 2003; 16: 178-83.
  • 112. Richard IH, Kurlan R, Parkinson Study Group. A survey of antidepressant use in Parkinson’s disease. Neurology 1997; 49: 1168-70.
  • 113. Alexopoulos GS, Katz IR, Reynolds CF III, et al. The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgrad Med (Spec Rep) 2001; October: 1-86.
  • 114. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord 2005; 20: 1161-9.
  • 115. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson’s disease treated with citalopram: a placebo-controlled trial. Nordic Journal of Psychiatry 1998; 52:163-9.
  • 116. Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry 2003; 18: 552-4.
  • 117. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson’s disease and depression. Neurology 2009; 72: 886-92.
  • 118. Richard I, McDermott M, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson’s disease. Neurology 2012; 78: 1229-36.
  • 119. Andersen J, Aabro E, Gulmann N, et al. Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with l-dopa. Acta Neurol Scand 1980; 62: 210-19.
  • 120. Emre M. Treatment of dementia associated with Parkinson’s disease. Parkinsonism Relat Disord 2007; 13(Suppl. 3): S457-S461.
  • 121. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573-80.
  • 122. Walsh K, Bennett G. Parkinson’s disease and anxiety. Postgrad Med J 2001; 77: 89-93.
  • 123. Devos D, Moreau C, Maltete D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomized clinical trial. J Neurol Neurosurg Psychiatry 2014; 85: 668-74.
  • 124. Marin RS, Fogel BS, Hawkins J, et al. Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 1995; 7: 23-30.
  • 125. Shulman LM. Apathy in patients with Parkinson’s disease. Int Rev Psychiatry 2000; 12: 298-306.
  • 126. Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 136: 1568-77.
  • 127. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 15: 201-11.
  • 128. Dewey RB, O’Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology 2000; 55: 1753-4.
  • 129. Weiner WJ, Minagar A, Shulman LM. Quetiapine for l-dopa-induced psychosis in PD. Neurology 2000; 54: 1538.
  • 130. Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson’s disease. J Neurol 2001; 248(Suppl. 3): III12-III21.
  • 131. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001; 56 (Suppl. 5): S1-S88.
  • 132. Thomsen TR, Panisset M, Suchowersky O, et al. Impact of standard of care for psychosis in Parkinson disease. J Neurol Neurosurg Psychiatry 2008; 79: 1413-15.
  • 133. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969-77.
  • 134. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613-18.
  • 135. Leroi I, Overshott R, Byrne E, et al. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord 2009; 24: 1217-40.
  • 136. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev 2006; CD004747.
  • 137. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20: 938-44.
  • 138. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-9.
  • 139. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509-18.
  • 140. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21: 1899-907.
  • 141. Reading PJ, Luce AK, McKeith IJ. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171-95.
  • 142. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor responses to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003; 18: 937-41.
  • 143. Marras C, Kopp A, Qiu F, et al. Antipsychotic use in older adults with Parkinson’s disease. Mov Disord 2007; 22: 319-23.
  • 144. Factor SA, Molho E, Friedman JH. Risperidone and Parkinson’s disease. Mov Disord 2002; 17: 221-2.
  • 145. Fernandez HH, Trieschmann ME, Friedman.JH. Treatment of psychosis in Parkinson’s disease: safety considerations. Drug Saf 2003; 26: 643-59.
  • 146. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005; 20: 958-63.
  • 147. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 2007; 22: 313-18.
  • 148. Reddy S, Factor SA, Molho E, et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17: 676-81.
  • 149. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18: 510-14.
  • 150. Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol 2006; 253: 171-5.
  • 151. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383: 533-40.
  • 152. FDA Center for Drug Evaluation and Research. Information for healthcare professionals: conventional antipsychotics [16 June 2008]. (accessed 9 February 2009).
  • 153. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc 2009; 294: 1934-43.
  • 154. Setoguchi S, Wang PS, Brookhart MA, et al. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008; 56: 1644-50.
  • 155. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Can Med Assoc J 2007; 176: 627-32.
  • 156. Gill SS, Bronskill SE, Normand S-LT, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 775-86.
  • 157. Marras C, Gruneir A, Wang X, et al. Antipsychotics and mortality in Parkinsonism. Am J Geriatr Psychiatry 2012; 20: 149-58.
  • 158. Friedman JH. Atypical antipsychotics in the elderly with Parkinson’s disease and the ‘black box’ warning. Neurology 2006; 67: 564-6.
  • 159. Culo S, Mulsant B, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord 2010; 24: 360-4.
  • 160. APA Work Group on Alzheimer’s Disease and Other Dementias. American Psychiatric Association Practice Guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry 2007; 164(Suppl.): 5-56.
  • 161. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med 2007; 357: 1382-92.
  • 162. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson’s disease with modafinil. Clin Neuropharmacol 2002; 25: 111-14.
  • 163. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 2003; 18: 287-93.
  • 164. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/ quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006; 59: 780-7.
  • 165. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextrometho- rphan/quinidine: a randomized trial. Neurology 2004; 63: 1364-70.
  • 166. Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. Semin Clin Neuropsychiatry 2000; 5: 290-306.
 
Source
Found a mistake? Please highlight the word and press Shift + Enter  
< Prev   CONTENTS   Next >
 
Subjects
Accounting
Business & Finance
Communication
Computer Science
Economics
Education
Engineering
Environment
Geography
Health
History
Language & Literature
Law
Management
Marketing
Mathematics
Political science
Philosophy
Psychology
Religion
Sociology
Travel